SLC10A2 and metabolic dysfunction-associated steatotic liver disease: ASBT mediates the first and rate limiting step in bile acid absorption and its inhibition represents an attractive therapeutic target to reduce hepatic cholesterol toxicity in NAFLD/NASH (12).